Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Lessened by Capital International Investors

Capital International Investors reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,547,210 shares of the biopharmaceutical company's stock after selling 33,962 shares during the period. Capital International Investors owned approximately 3.34% of Xenon Pharmaceuticals worth $99,851,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its stake in shares of Xenon Pharmaceuticals by 140.3% in the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after acquiring an additional 1,414 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $101,000. KBC Group NV increased its stake in shares of Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 780 shares during the last quarter. Magnetar Financial LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $210,000. Finally, HighMark Wealth Management LLC boosted its stake in Xenon Pharmaceuticals by 22.0% during the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock valued at $239,000 after acquiring an additional 1,100 shares during the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 16,315 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.52% of the company's stock.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ:XENE traded down $0.46 during trading hours on Friday, hitting $37.75. The stock had a trading volume of 178,863 shares, compared to its average volume of 442,250. The stock's fifty day simple moving average is $34.83 and its 200 day simple moving average is $38.71. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -13.34 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price on the stock. Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. The Goldman Sachs Group decreased their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. StockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $56.78.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.